We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current RICFY market cap is 2.98B. The company's latest EPS is EUR 1.9917 and P/E is 28.14.
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 1.42B | 1.54B | 1.84B | 2.07B | 2.33B |
| Operating Income | 469.02M | 490.19M | 437.33M | 558.01M | 638.86M |
| Net Income | 354.98M | 385.97M | 312.34M | 389.21M | 416.51M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 2.71B | 2.82B | 4B | 4.21B | 5.13B |
| Total Liabilities | 1.44B | 1.43B | 2.45B | 2.52B | 3.26B |
| Total Equity | 1.28B | 1.38B | 1.55B | 1.69B | 1.88B |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | 403.58M | 491.65M | 461.69M | 485.32M | 569.92M |
| Investing | -131.56M | -87.5M | -767.12M | -379.62M | -844.94M |
| Financing | -264.29M | -355.94M | 341.28M | -168.91M | 372.11M |
| Market Cap | 2.98B |
| Price to Earnings Ratio | 28.14 |
| Price to Sales Ratio | 5.04 |
| Price to Cash Ratio | 36.35 |
| Price to Book Ratio | 6.24 |
| Dividend Yield | 2.14% |
| Shares Outstanding | 209.13M |
| Average Volume (1 week) | 1.82k |
| Average Volume (1 Month) | 1.36k |
| 52 Week Change | 9.20% |
| 52 Week High | 16.02 |
| 52 Week Low | 10.34 |
| Spread (Intraday) | 6.3 (31.03%) |
| Company Name | Recordati Industria Chimica E Farmaceutica SPA (PK) |
| Address |
via matteo civitali 1 milan, lombardy 20148 |
| Website | https://www.recordati.it |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
